These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27817858)

  • 1. [Systemic neoadjuvant therapy of luminal breast cancer in 2016].
    Cottu PH
    Bull Cancer; 2017 Jan; 104(1):69-78. PubMed ID: 27817858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infiltrating lobular carcinoma of the breast: systemic treatment.
    Farese SA; Aebi S
    Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
    Bychkovsky BL; Dizon DS; Sikov WM
    Clin Obstet Gynecol; 2016 Dec; 59(4):756-771. PubMed ID: 27741213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
    Chen LR
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):218-21. PubMed ID: 20654118
    [No Abstract]   [Full Text] [Related]  

  • 8. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development: neoadjuvant opportunities in breast cancer.
    Rastogi P; Geyer CE; Mamounas EP; DeMichele A
    Am Soc Clin Oncol Educ Book; 2013; ():73-9. PubMed ID: 23714461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
    Esposito A; Criscitiello C; Curigliano G
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):51-5. PubMed ID: 26063887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer.
    Matsunuma R; Watanabe T; Hozumi Y; Koizumi K; Ito Y; Maruyama S; Ogura H; Goto K; Mori H; Sawai N; Shiiya N
    Breast Cancer; 2020 Sep; 27(5):819-827. PubMed ID: 32144735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
    Cottu P; Marangoni E; Assayag F; de Cremoux P; Vincent-Salomon A; Guyader Ch; de Plater L; Elbaz C; Karboul N; Fontaine JJ; Chateau-Joubert S; Boudou-Rouquette P; Alran S; Dangles-Marie V; Gentien D; Poupon MF; Decaudin D
    Breast Cancer Res Treat; 2012 Jun; 133(2):595-606. PubMed ID: 22002565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.